Skip to main content
. 2022 May 15;26(9):909–916. doi: 10.1007/s10157-022-02231-y

Table 2.

Baseline characteristics of patients with new-onset and relapse of nephrotic syndrome after receiving COVID-19 vaccination

Characteristic All cases (n = 27) New-onset (n = 6) Relapse
(n = 21)
Age (years)
  ≤ 19 3 0 3
 20–29 4 0 4
 30–39 3 0 3
 40–49 2 1 1
 50–59 2 0 2
 60–69 6 1 5
  ≥ 70 7 4 3
Sex
 Female 12 2 10
 Male 15 4 11
Treatments before this event (multiple answers allowed)
 No treatment 10 6 4
 Oral corticosteroid 15 0 15
Steroid pulse therapy 3 0 3
 Immunosuppressive therapy (except for rituximab) 10 0 10
 Rituximab 3 0 3
 RAS-I 7 0 7
 Antiplatelet drugs 1 0 1
Type of the vaccine
 COMIRNATY Intramuscular Injection (Pfizer-BioNTech) 23 5 18
 COVID-19 Vaccine Moderna Intramuscular Injection (Moderna/Takeda) 1 0 1
 Unknown 3 1 2
Vaccination dose
 First dose 8 1 7
 Second dose 18 4 14
 Both first and second doses 1 1 1
Histopathological diagnoses revealed by the kidney biopsy
 Minimal change disease 12 2 10
 Focal segmental glomerulosclerosis 2 0 2
 Membranous nephropathy 4 2 2
 IgA nephropathy 2 1 1
 Membranoproliferative glomerulonephritis 1 0 1
 C3 glomerulopathy 2 0 2
 Unknown/did not answer 4 1 3
Adverse reactions (multiple answers allowed)
 Fever (≥ 37.5 ℃) 5 0 5
 Fatigue 8 0 8
 Headache 1 0 1
 Chills 0 0 0
 Muscle pain 6 2 4
 Pain at the application site 1 0 1
 Joint pain 2 0 2
 None 2 0 2
 Unknown 8 4 4

COVID-19 coronavirus disease 2019, RAS-I renin–angiotensin system inhibitor